23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ULTRAGENYX PHARMACEUTICAL INC. › 2023-2024

ULTRAGENYX PHARMACEUTICAL INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed June 21, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 326Asset managers, any item
  • 2,242Fund votes
  • June 18, 2024Meeting date

Results at a glance

Meeting of June 18, 2024: 6 items on ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed June 21, 2024: 2 approved · 4 passed (calculated).

Dissent

Notable dissent: 2 directors (11.1%, 10.6% against); 1 say-on-pay vote (73.9% support); 1 other board item (30.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Nantahala Capital (13F, 2.3%, as of September 30, 2026)

Explore ULTRAGENYX PHARMACEUTICAL INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ULTRAGENYX PHARMACEUTICAL INC.

These tallies are ULTRAGENYX PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 21, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ULTRAGENYX PHARMACEUTICAL INC. — official shareholder meeting results, meeting held June 18, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Deborah Dunsire, M.D. 66,396,499---- 7,865,3484,273,815 89%Passed (calculated)—
Elect Director: Michael Narachi 66,013,202---- 8,248,6454,273,815 89%Passed (calculated)—
Elect Director: Corsee Sanders, Ph.D. 68,077,817---- 6,184,0304,273,815 92%Passed (calculated)—
Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan. The votes on Proposal 2 were 51,942,75222,299,71819,377 --4,273,815 70%Approved—
Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal yea 77,155,4521,362,19418,016 ---- 98%Approved—
4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as described 54,803,35119,320,182138,314 --4,273,815 74%Passed (calculated)—

Source: ULTRAGENYX PHARMACEUTICAL INC., Form 8-K, filed with the SEC on June 21, 2024 — read the filing on EDGAR.

How asset managers voted at the ULTRAGENYX PHARMACEUTICAL INC. 2023-2024 meeting

326 asset managers disclosed a vote on at least one ULTRAGENYX PHARMACEUTICAL INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Corsee Sanders, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 68,077,817WITHHELD: 6,184,030
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Nominees: Corsee D. Sanders, Ph.D.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Corsee Sanders, Ph.D.”): 68,077,817 for, 6,184,030 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 28,421,970 for, 3,572,979 withheld.

FOR
FOR: 28,421,970WITHHOLD: 3,572,979
Largest asset managers voting on “Nominees: Corsee D. Sanders, Ph.D.” at ULTRAGENYX PHARMACEUTICAL INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,392,5410 00For
T. Rowe Price00 02,612,411Withhold
Fidelity2,165,8410 00For
Federated Hermes1,882,3500 00For
BlackRock1,744,5750 00For
Hartford1,581,5560 00For
State Street1,517,1060 0324For
Legg Mason1,333,9880 00For
Invesco867,0350 00For
TOUCHSTONE FUNDS GROUP TRUST776,8770 00For
BNY Mellon490,5400 00For
Charles Schwab488,1430 00For
AllianceBernstein416,3600 00For
MUTUAL FUND SERIES TRUST359,0000 00For
TIAA335,7980 00For
AB DISCOVERY GROWTH FUND, INC.331,3210 00For
Advantage Advisers Xanthus Fund, L.L.C.324,3580 00For
First Trust280,0340 00For
John Hancock215,4220 049,165Mixed
Northwestern Mutual259,1500 00For
MFS256,3850 00For
Principal89,0430 0133,658Mixed
FINANCIAL INVESTORS TRUST00 0206,002Withhold
Goldman Sachs00 0204,203Withhold
Equitable159,2470 016,828Mixed

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Elect Director: Deborah Dunsire, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 66,396,499WITHHELD: 7,865,348
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Nominees: Deborah Dunsire, M.D.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Deborah Dunsire, M.D.”): 66,396,499 for, 7,865,348 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 26,956,199 for, 5,038,733 withheld.

FORWITHHOLD
FOR: 26,956,199WITHHOLD: 5,038,733
Largest asset managers voting on “Nominees: Deborah Dunsire, M.D.” at ULTRAGENYX PHARMACEUTICAL INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,392,5410 00For
T. Rowe Price00 02,612,411Withhold
Fidelity2,144,0920 021,749For
Federated Hermes1,882,3500 00For
BlackRock1,744,5750 00For
Hartford1,581,5560 00For
State Street1,517,1060 0324For
Legg Mason1,333,9880 00For
Invesco867,0350 00For
TOUCHSTONE FUNDS GROUP TRUST776,8770 00For
BNY Mellon8,9580 0481,582Withhold
Charles Schwab488,1430 00For
AllianceBernstein00 0416,360Withhold
MUTUAL FUND SERIES TRUST359,0000 00For
TIAA335,7980 00For
AB DISCOVERY GROWTH FUND, INC.00 0331,321Withhold
Advantage Advisers Xanthus Fund, L.L.C.324,3580 00For
First Trust280,0340 00For
John Hancock215,4220 049,165Mixed
Northwestern Mutual259,1500 00For
MFS256,3850 00For
Principal7,6740 0215,027Withhold
FINANCIAL INVESTORS TRUST00 0206,002Withhold
Goldman Sachs00 0204,203Withhold
Equitable25,8570 0150,218Mixed

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Elect Director: Michael Narachi

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 66,013,202WITHHELD: 8,248,645
Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Nominees: Michael Narachi

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Michael Narachi”): 66,013,202 for, 8,248,645 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 102 asset managers below reported 26,954,329 for, 5,040,586 withheld.

FORWITHHOLD
FOR: 26,954,329WITHHOLD: 5,040,586
Largest asset managers voting on “Nominees: Michael Narachi” at ULTRAGENYX PHARMACEUTICAL INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,392,5410 00For
T. Rowe Price00 02,612,411Withhold
Fidelity2,144,0920 021,749For
Federated Hermes1,882,3500 00For
BlackRock1,744,5750 00For
Hartford1,581,5560 00For
State Street1,517,1060 0324For
Legg Mason1,333,9880 00For
Invesco867,0350 00For
TOUCHSTONE FUNDS GROUP TRUST776,8770 00For
BNY Mellon8,9580 0481,582Withhold
Charles Schwab488,1430 00For
AllianceBernstein00 0416,360Withhold
MUTUAL FUND SERIES TRUST359,0000 00For
TIAA335,7980 00For
AB DISCOVERY GROWTH FUND, INC.00 0331,321Withhold
Advantage Advisers Xanthus Fund, L.L.C.324,3580 00For
First Trust280,0340 00For
John Hancock215,4220 049,165Mixed
Northwestern Mutual259,1500 00For
MFS256,3850 00For
Principal7,6740 0215,027Withhold
FINANCIAL INVESTORS TRUST00 0206,002Withhold
Goldman Sachs00 0204,203Withhold
Equitable25,8570 0150,218Mixed

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan. The votes…

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

70% Approved · of votes cast

FOR 70%AGAINST
FOR: 51,942,752AGAINST: 22,299,718
Details: description as filed, official tally, votes by 103 asset managers

Description as filed by funds: Approval of the Amended and Restated 2023 Incentive Plan.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 2: Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 51,942,752 for, 22,299,718 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 – Approval of the A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the A&R 2023 Plan.”
Support: 70% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 100 asset managers voting on “Approval of the Amended and Restated 2023 Incentive Plan.” at ULTRAGENYX PHARMACEUTICAL INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,392,5410 00For
T. Rowe Price2,612,4110 00For
Fidelity1,292,666873,175 00Mixed
Federated Hermes1,882,3500 00For
BlackRock1,744,5750 00For
Hartford1,581,5560 00For
State Street1,5581,515,872 00Against
Legg Mason1,333,9880 00For
Invesco0867,035 00Against
TOUCHSTONE FUNDS GROUP TRUST776,8770 00For
BNY Mellon0490,540 00Against
Charles Schwab488,1430 00For
AllianceBernstein0416,360 00Against
MUTUAL FUND SERIES TRUST359,0000 00For
TIAA0335,798 00Against
AB DISCOVERY GROWTH FUND, INC.0331,321 00Against
Advantage Advisers Xanthus Fund, L.L.C.0324,358 00Against
First Trust0280,034 00Against
John Hancock49,165215,422 00Mixed
Northwestern Mutual259,1500 00For
MFS0256,385 00Against
Principal133,65889,043 00Mixed
FINANCIAL INVESTORS TRUST206,0020 00For
Goldman Sachs0204,203 00Against
Equitable42,685133,390 00Mixed

Fund voting reports, all 100 managers: 23,925,313 for, 7,917,068 against, 11,435 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “Approval of the Amended and Restated 2023 Incentive Plan.” at ULTRAGENYX PHARMACEUTICAL INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
First Light Asset Management, LLC737,4960 00For
Altium Capital Management LP140,0000 00For
Keel Point, LLC041 00Against

Institutional-manager reports, all 3 managers: 877,496 for, 41 against.

Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted…

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 9 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%AGAINST
FOR: 54,803,351AGAINST: 19,320,182

Prior year: 94.7% for (June 7, 2023 meeting) ▼ 20.7 pts

Details: description as filed, official tally, votes by 324 asset managers

Description as filed by funds: Advisory (non-binding) vote to approve the compensation of our named executive officers.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its ”): 54,803,351 for, 19,320,182 against, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 101 asset managers voting on “Advisory (non-binding) vote to approve the compensation of our named executive officers.” at ULTRAGENYX PHARMACEUTICAL INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard9,651,123741,418 00Mixed
T. Rowe Price2,612,4110 00For
Fidelity2,144,09221,749 00For
Federated Hermes1,882,3500 00For
BlackRock1,744,5750 00For
Hartford1,581,5560 00For
State Street1,515,4132,017 00For
Legg Mason01,333,988 00Against
Invesco867,0350 00For
TOUCHSTONE FUNDS GROUP TRUST776,8770 00For
BNY Mellon8,958481,582 00Against
Charles Schwab488,1430 00For
AllianceBernstein0416,360 00Against
MUTUAL FUND SERIES TRUST359,0000 00For
TIAA0335,798 00Against
AB DISCOVERY GROWTH FUND, INC.0331,321 00Against
Advantage Advisers Xanthus Fund, L.L.C.0324,358 00Against
First Trust0280,034 00Against
John Hancock125,670138,917 00Mixed
Northwestern Mutual259,1500 00For
MFS0256,385 00Against
Principal133,65889,043 00Mixed
FINANCIAL INVESTORS TRUST206,0020 00For
Goldman Sachs0204,203 00Against
Equitable22,115153,960 00Mixed

Fund voting reports, all 101 managers: 25,450,499 for, 6,421,837 against, 11,435 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 251 asset managers voting on “Advisory (non-binding) vote to approve the compensation of our named executive officers.” at ULTRAGENYX PHARMACEUTICAL INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP6,742,2860 00For
Wellington3,746,4520 00For
T. Rowe Price3,308,7460 00For
SANDS CAPITAL MANAGEMENT, LLC2,755,2490 00For
State Street2,557,09537,242 00For
BlackRock2,420,14019,967 00For
Clearbridge Investments, LLC02,303,927 00Against
Federated Hermes1,882,3540 00For
Rock Springs Capital Management LP1,756,0550 00For
SUVRETTA CAPITAL MANAGEMENT, LLC01,676,811 00Against
BAKER BROS. ADVISORS LP1,466,5470 00For
Man Group plc01,454,680 00Against
GEODE CAPITAL MANAGEMENT, LLC1,340,8690 00For
AllianceBernstein01,212,260 00Against
Invesco952,1690 00For
Fidelity750,5520 00For
First Light Asset Management, LLC737,4960 00For
ALKEON CAPITAL MANAGEMENT LLC0693,685 00Against
Candriam S.C.A.0606,897 00Against
Avidity Partners Management LP604,5430 00For
Woodline Partners LP588,8380 00For
Newton Investment Management North America, LLC0560,076 00Against
BNP Paribas Asset Management Holding S.A.0507,513 00Against
PICTET ASSET MANAGEMENT SA0501,296 00Against
Charles Schwab499,1990 00For

Institutional-manager reports, all 251 managers: 36,760,821 for, 15,117,314 against, 122,555 abstained, 186 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 77,155,452AGAINST: 1,362,194

Prior year: 98.6% for (June 7, 2023 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 102 asset managers

Description as filed by funds: Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 77,155,452 for, 1,362,194 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of ULTRAGENYX PHARMACEUTICAL INC.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, 29,938 for).

The 102 asset managers below reported 31,968,225 for, 14,128 against, 11,435 abstained.

FOR
FOR: 31,968,225AGAINST: 14,128ABSTAIN: 11,435
Largest asset managers voting on “Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for th” at ULTRAGENYX PHARMACEUTICAL INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard10,392,5410 00For
T. Rowe Price2,612,4110 00For
Fidelity2,165,8410 00For
Federated Hermes1,882,3500 00For
BlackRock1,744,5750 00For
Hartford1,581,5560 00For
State Street1,517,195235 00For
Legg Mason1,333,9880 00For
Invesco867,0350 00For
TOUCHSTONE FUNDS GROUP TRUST776,8770 00For
BNY Mellon490,5400 00For
Charles Schwab488,1430 00For
AllianceBernstein416,3600 00For
MUTUAL FUND SERIES TRUST359,0000 00For
TIAA335,7980 00For
AB DISCOVERY GROWTH FUND, INC.331,3210 00For
Advantage Advisers Xanthus Fund, L.L.C.324,3580 00For
First Trust280,0340 00For
John Hancock264,5870 00For
Northwestern Mutual259,1500 00For
MFS256,3850 00For
Principal222,7010 00For
FINANCIAL INVESTORS TRUST206,0020 00For
Goldman Sachs204,2030 00For
Equitable176,0750 00For

Showing the 25 largest of 102 asset managers. All 102 are in the interactive database (link above).

Largest ULTRAGENYX PHARMACEUTICAL INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 83,094,037 shares outstanding at the time of that meeting.

Fund voting reports: top ULTRAGENYX PHARMACEUTICAL INC. shareholders by shares voted on “Advisory (non-binding) vote to approve the compensation of our named executive officers.”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 12.51%
2T. Rowe Price 3.14%
3Fidelity 2.61%
4Federated Hermes 2.27%
5BlackRock 2.10%
6Hartford 1.90%
7State Street 1.83%
8Legg Mason 1.61%
9Invesco 1.04%
10TOUCHSTONE FUNDS GROUP TRUST 0.93%
Institutional-manager reports: top ULTRAGENYX PHARMACEUTICAL INC. shareholders by shares voted on “Advisory (non-binding) vote to approve the compensation of our named executive officers.”, 2023-2024
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 8.11%
2Wellington 4.51%
3T. Rowe Price 3.98%
4SANDS CAPITAL MANAGEMENT, LLC 3.32%
5State Street 3.12%
6BlackRock 2.94%
7Clearbridge Investments, LLC 2.77%
8Federated Hermes 2.27%
9Rock Springs Capital Management LP 2.11%
10SUVRETTA CAPITAL MANAGEMENT, LLC 2.02%

Reported ULTRAGENYX PHARMACEUTICAL INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ULTRAGENYX PHARMACEUTICAL INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Vanguard Group10,132,728 12.19%Form 13F, quarter ended March 31, 2024
FMR (Fidelity)7,283,296 8.77%Form 13F, quarter ended March 31, 2024
BlackRock6,425,263 7.73%Form 13F, quarter ended March 31, 2024
Wellington Management4,097,975 4.93%Form 13F, quarter ended March 31, 2024
JPMorgan Chase4,011,429 4.83%Form 13F, quarter ended March 31, 2024
T. Rowe Price3,568,873 4.29%Form 13F, quarter ended March 31, 2024
State Street2,851,250 3.43%Form 13F, quarter ended March 31, 2024
Geode Capital1,339,826 1.61%Form 13F, quarter ended March 31, 2024
BNY Mellon911,656 1.10%Form 13F, quarter ended March 31, 2024
Morgan Stanley910,183 1.10%Form 13F, quarter ended March 31, 2024

Percentages above are of 83,094,037 shares outstanding, as reported by ULTRAGENYX PHARMACEUTICAL INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ULTRAGENYX PHARMACEUTICAL INC.'s shareholder meeting held June 18, 2024, in the 2023-2024 proxy season, 326 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 2,242 separate fund positions. On the most widely held item on that ballot — Advisory (non-binding) vote to approve the compensation of our named executive officers. — FOR was 74% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ULTRAGENYX PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 21, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ULTRAGENYX PHARMACEUTICAL INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ULTRAGENYX PHARMACEUTICAL INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ULTRAGENYX PHARMACEUTICAL (RARE) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ultragenyx-pharmaceutical-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.